Ligachem Biosciences, Inc.
Clinical trials sponsored by Ligachem Biosciences, Inc., explained in plain language.
-
New drug candidate takes on stubborn lung infection
Disease control CompletedThis study tests whether adding delpazolid to standard treatment can reduce bacterial levels in people with hard-to-treat Mycobacterium abscessus lung infections. Participants take delpazolid tablets daily for 12 weeks, with the option to continue up to one year if there is clini…
Phase: PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New TB drug combo shows promise in early trial
Disease control CompletedThis phase IIb trial tested an experimental antibiotic called delpazolid, added to a standard three-drug regimen (bedaquiline, delamanid, moxifloxacin), in 76 adults with newly diagnosed, drug-sensitive pulmonary tuberculosis. The main goals were to check safety and how the drug …
Phase: PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:01 UTC